<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="349">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068353</url>
  </required_header>
  <id_info>
    <org_study_id>STEADI-09</org_study_id>
    <secondary_id>2009-013400-31</secondary_id>
    <nct_id>NCT01068353</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Etanercept in Alzheimer's Disease</brief_title>
  <acronym>STEADI-09</acronym>
  <official_title>A Phase 2, Double-blind, Placebo-controlled Study of the Safety and Tolerability of Etanercept in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hampshire Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to determine the safety and tolerability of etanercept in&#xD;
      subjects with Alzheimer's Disease. The effects of etanercept on cognitive, behavioural,&#xD;
      functional and immunological outcomes will be examined as secondary aims.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Alzheimer's Disease Assessment Scale - Cognitive Section (ADAS-cog) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Neuropsychiatric Inventory (NPI) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Clinician's Global Impression of Change (CGIC) and Carer's Impression of Change (Carer-IC) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Mini-Mental State Examination (MMSE) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Sickness Behaviour Scale between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish whether a pro-inflammatory baseline cytokine profile predicts better response to treatment with etanercept</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the effects of etanercept on inflammatory markers in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease, and the relationship of these factors with clinical outcome</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg given as a once weekly subcutaneous injection</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection given once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged &gt; 54 years&#xD;
&#xD;
          -  Have a minimum of 7 years of education&#xD;
&#xD;
          -  Be able to hear, read, write and perform study neuropsychological tests in English&#xD;
&#xD;
          -  Have adequate visual and auditory acuity to allow neuropsychological testing based on&#xD;
             the research clinician's judgement&#xD;
&#xD;
          -  Fulfil Diagnostic &amp; Statistical Manual (DSM-IV-TR)criteria for diagnosis of dementia&#xD;
             of the Alzheimer type&#xD;
&#xD;
          -  Have a diagnosis of probable Alzheimer's Disease (National Institute of Neurological&#xD;
             and Communicative Disorders and Stroke and the Alzheimer's Disease and Related&#xD;
             Disorders Association (NINCDS-ADRDA) criteria)&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE) score &lt; 27 and &gt; 10 points.&#xD;
&#xD;
          -  To be currently taking and have been taking a cholinesterase inhibitor for a minimum&#xD;
             period of 3 months prior to the day of inclusion into the study or to have been not&#xD;
             been taking a cholinesterase inhibitor for a minimum period of 3 months prior to the&#xD;
             day of inclusion into the study&#xD;
&#xD;
          -  Have an informant who spends at least 24 hours per week with the patient and may be a&#xD;
             close friend or a neighbour, not necessarily a close relative, spouse, son or&#xD;
             daughter. He/she should be the same throughout the study and should be present at all&#xD;
             visits. If it becomes necessary, a change of informant can be made but this must be&#xD;
             clearly documented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or refusal to provide informed consent from patient or caregiver&#xD;
&#xD;
          -  Absence of informant&#xD;
&#xD;
          -  Unlikely to cooperate in the study, not able to attend scheduled examinations and&#xD;
             visits, or not able to follow study instructions&#xD;
&#xD;
          -  Participation in another study with administration of any investigational drug in the&#xD;
             previous 3 months or already enrolled in another study&#xD;
&#xD;
          -  Parkinson's Disease, Dementia with Lewy Bodies or clinically significant Parkinsonian&#xD;
             symptoms&#xD;
&#xD;
          -  Vascular disorder (modified Hachinski Ischaemic Scale score &gt; 4)&#xD;
&#xD;
          -  Recent Transient Ischaemic Attack (TIA) - within the last 3 months&#xD;
&#xD;
          -  Signs of major cerebrovascular disease on MRI or CT scan, if performed prior to entry&#xD;
             into study (i.e. presence of infarction in greater than 25% of white matter, more than&#xD;
             1 lacune within basal ganglia, more than 2 lacunes in white matter)&#xD;
&#xD;
          -  Any other previous or ongoing chronic or recurrent disease of the central nervous&#xD;
             system, including demyelinating disease or psychiatric diseases, that may have an&#xD;
             impact on cognitive performance, left to the research clinician's judgement&#xD;
&#xD;
          -  Any of the following laboratory abnormalities at the screening visit:&#xD;
&#xD;
             i) Clinically significant Vitamin B12 levels less than the lower limit of normal ii)&#xD;
             Clinically significant folate levels less than the lower limit of normal iii)&#xD;
             Clinically significant thyroid-stimulating hormone (TSH) levels greater than the upper&#xD;
             limit of normal and a clinically significant free thyroxine (FT4) level lower than the&#xD;
             lower limit of normal&#xD;
&#xD;
          -  Patients with previous or present history of severe or unstable medical conditions&#xD;
             (e.g. hypertension, diabetes left to the research clinician's judgement)&#xD;
&#xD;
          -  Current alcohol &gt;35 units per week for men, or &gt;28 units per week for women, or drug&#xD;
             abuse at the discretion of the research clinician&#xD;
&#xD;
          -  Surgical intervention planned during the study period.&#xD;
&#xD;
          -  Treatment with immunosuppressive drugs and/or oral prednisone greater than 10mg/day&#xD;
             within the past 90 days&#xD;
&#xD;
          -  Treatment with Memantine within the past 3 months&#xD;
&#xD;
          -  Vaccination or immunization with any live vaccine (eg: polio, rubella, yellow fever)&#xD;
             or the pneumococcal vaccine within the past 30 days.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Severe hepatic, renal or cardiac disease.&#xD;
&#xD;
          -  Previous use of a Tumour Necrosis Factor-alpha (TNFα) agent.&#xD;
&#xD;
          -  Known skin photosensitivity.&#xD;
&#xD;
          -  Infection in past 4 weeks or active infection.&#xD;
&#xD;
          -  Heart failure: New York Heart Association (NYHA) Grade 3-4.&#xD;
&#xD;
          -  History of blood disorders or current WCC ≤ 3.5 x 109/l; platelet count ≤ 100x109/l ;&#xD;
             Hb ≤ 10g/dl.&#xD;
&#xD;
          -  Active or latent tuberculosis&#xD;
&#xD;
          -  Rheumatoid arthritis; psoriasis; psoriatic arthritis or ankylosing spondylitis&#xD;
&#xD;
          -  Septic arthritis in past 12 months&#xD;
&#xD;
          -  Sepsis of prosthesis in past 12 months&#xD;
&#xD;
          -  Chronic leg ulcers&#xD;
&#xD;
          -  Indwelling urinary catheter&#xD;
&#xD;
          -  Pulmonary fibrosis&#xD;
&#xD;
          -  History of neoplasms / malignancies in past 5 years&#xD;
&#xD;
          -  Pre-malignant conditions including Barrett's oesophagus; cervical dysplasia; large&#xD;
             bowel polyps&#xD;
&#xD;
          -  Any relevant acute or chronic abnormality detected during the physical and&#xD;
             neurological examinations. Electrocardiogram (ECG) or laboratory tests likely to&#xD;
             interfere with the study evaluations in the research clinician's judgement&#xD;
&#xD;
          -  Previous exposure to amyloid vaccines, monoclonal antibodies or intravenous&#xD;
             immunoglobulins meant to treat Alzheimer's disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Memory Assessment and Research Centre, Moorgreen Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO30 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>TNF-alpha</keyword>
  <keyword>Etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 29, 2021</submitted>
    <returned>February 17, 2021</returned>
    <submitted>March 5, 2021</submitted>
    <returned>March 31, 2021</returned>
    <submitted>December 16, 2021</submitted>
    <returned>March 4, 2022</returned>
    <submitted>June 28, 2022</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

